

VOTE NO ON AB 2203



Gives Pharma an Open Door to Raise Drug Prices With No Accountability

FACT:

Pharma's Drug Prices are too High.

FACT:

AB 2203 Makes it Easier for Big Pharma to Charge Any Amount it Wishes for the Price of Insulin.

FACT:

AB 2203 Will Increase Health Plan Premiums by \$20 million in just the first year.

The price drug companies set for insulin is far too high. In fact, recently reported prices for insulin by drug manufacturers show they can range from **\$800 to \$1,400 per treatment**.*

Co-pay caps are already the law of the land in California and lowering these limits will do nothing to lower the price of insulin itself. It is merely a Band-Aid that will not heal the underlying problem: The high price Big Pharma sets for insulin.

Three Major Problems with AB 2203

- 1 Imposing lower co-pay limits does nothing to lower the price of the actual drug.
- 2 A co-pay limit does not limit what Big Pharma can charge purchasers for Insulin.
- 3 Gives big pharma too much power to set any price it wishes for insulin, ultimately driving up the cost of care by increasing premiums consumers pay by an estimated \$20 million in the first year alone.**

Ever-increasing prices set by Big Pharma = increased health care costs for everyone.

NO on AB 2203


*(OSHPD SB17 Drug Cost Increase Report September 2019)

** (CHBRP Report March 2020)

VOTE NO ON AB 2203



One drug to help treat type 2 diabetes, Jardiance, increased by over \$83 and now costs over \$1,400. Cycloset, which also helps to treat type 2 diabetes, increased its price by nearly \$50 to now cost over \$800.



Source: OSHPD

NON-STOP PRICE HIKES

INSULIN

55%

is the average rise in cost since 2014

2002
\$40

2013
\$130

2019
\$300+

AND PRICES CONTINUE TO CLIMB

Source: JAMA, Business Insider, GoodRx

\$1 OUT OF EVERY \$7

SPENT ON HEALTH CARE IS USED ON DIABETES AND ITS COMPLICATIONS



Source: American Diabetes Association


PRICE INCREASES HAVE NOT SLOWED, DESPITE PROMISES FROM PHARMACEUTICAL COMPANIES.

Sources: New York Times, Axios, Good Rx

HUMALOG: SAME DRUG, NEW PRICE

The price for a standard 10 ml vial of one of the most popular insulin brands, Humalog:

Source: The Hill



A PATENTED ADVANTAGE

Unlike most drugs that have been around for decades — no generic alternatives to insulin exist. The pharmaceutical companies that control the market make small tweaks to extend the patents — gaming the system and keeping generics off the market.

Sources: New York Times, Axios, Good Rx

For more information, please go to RunawayRx.org